Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pathocil

(Dicloxacillin)

ApprovedSmall molecule

WWyeth-Lederle Vaccines

Pathocil is one of 63 small molecule programs targeting Endocarditis. It is currently in Approved.

3

Indications

5

Total Trials

1

Active Trials

62

Competitors

3

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

EndocarditisRecruiting

Infective EndocarditisActive, not recruiting

Atopic DermatitisActive, not recruiting

EndocarditisApproved

Recruiting

Infective EndocarditisApproved

Active, not recruiting

Atopic DermatitisApproved

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Cytosar

Fludara

Adtralza

Pathocil

WWyeth-Lederle Vaccines

Amlitelimab

DUPIXENT

Certolizumab

Johnson & Johnson

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Endocarditis

NCT05398679

Clinical

Trials by Indication[1]

Infections1 trial

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

Completed· Pfizer logo

Pfizer·Phase 3·NCT00037050·739 enrolled

Absorption1 trial

The Effect of Dicloxacillin on Oral Absorption of Drugs

Completed·UUniversity of Southern Denmark·Phase 1·NCT05073627·12 enrolled

Drug Interactions1 trial

Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.

Completed·PPer Damkier·Phase 1·NCT02983890·12 enrolled

Atopic Dermatitis1 trial

Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis

Unknown status·JJacob Pontoppidan Thyssen·Phase 4·NCT05578482·45 enrolled

Endocarditis1 trial

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Approved·NCT05398679·360 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PATHOCIL

NDA NDA050011

Jan 1, 1982

DYNAPEN

NDA NDA050337

Jan 1, 1982

PATHOCIL

NDA NDA050092

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Dicloxacillin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dicloxacillin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dicloxacillin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050011). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWyeth-Lederle Vaccines

Related News